The first patient in the phase 2 Multiple Myeloma study was dosed and an IND submission to FDA is planned for MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC in H2 2017.
The Board of Directors of Molecular Partners has unanimously appointed Patrick Amstutz, Ph.D. and co-founder of the company, as Chief Executive Officer and decided to nominate him to become a member of the Board of Directors.
At the AGM of Molecular Partners, the shareholders of the company approved all motions proposed by the Board of Directors with a large majority and elected Gwen Fyfe as new member of the Board.
Molecular Partners’ strategic partner Allergan has completed the patient recruitment in the two global AMD Phase 3 studies of abicipar pegol.
Molecular Partners announced its Quarterly Management Statement and key financial highlights for Q1 2017.
Molecular Partners published the Invitation to the Annual General Meeting 2017 which will be held on Thursday, May 11, 2017, 2.00 pm CET, at the SIX Swiss Exchange, Zurich.
Molecular Partners AG announces that Christian Zahnd, co-founder and former CEO of the company, has decided not to stand for re-election as member of the Board at the AGM 2017 due to health reasons. The Board of Directors has decided to appoint him as Honorary Chairman of the Board of the company.
Molecular Partners discloses change in shareholder base
Molecular Partners Published its Audited Financial Results and Annual Report 2016
Molecular Partners will present at at the Cowen and Company 37th Annual Healthcare Conference in Boston on March 07, 2017.